Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated

Staging and Genetic Markers

At a Glance

In CLL, genetic markers from FISH and molecular testing are just as important as traditional staging. Mutated IGHV and del(13q) suggest a slower-growing disease, while del(17p), TP53 mutations, and unmutated IGHV indicate higher risk, guiding doctors toward targeted therapies over chemotherapy.

In the past, doctors relied entirely on what they could see and feel to understand CLL. Today, while we still use traditional staging, we look much deeper into the DNA of your cancer cells to predict how the disease will behave [1][2].

Traditional Staging: Rai and Binet

The Rai system (used mostly in the US) and the Binet system (used mostly in Europe) are clinical frameworks that categorize CLL based on blood counts and physical findings [3].

  • Rai Staging (0 to IV):
    • Stage 0: High white blood cell count only (low risk).
    • Stages I–II: Enlarged lymph nodes, liver, or spleen (intermediate risk).
    • Stages III–IV: Low red blood cells (anemia) or low platelets (thrombocytopenia) (high risk) [3][4].
  • Binet Staging (A, B, or C):
    • Binet A: Fewer than 3 areas of enlarged lymph tissue.
    • Binet B: 3 or more areas of enlarged lymph tissue.
    • Binet C: Presence of anemia or low platelets [3][4].

While these systems are helpful, they cannot tell us which early-stage patients will stay stable for decades and which might progress more quickly [5]. That is where genetic markers come in.

The Power of Genetic Markers

Modern treatment planning relies heavily on tests like FISH (Fluorescence In Situ Hybridization) and molecular sequencing [1].

1. IGHV Mutation Status: The Counterintuitive Fact

In most cancers, “mutated” sounds like a bad thing. However, in CLL, having mutated IGHV is a positive sign [6].

  • Mutated (M-CLL): These cancer cells are more “mature” and tend to grow very slowly [6]. Patients often stay in “watch and wait” for a long time [7].
  • Unmutated (U-CLL): These cells are more “primitive” and aggressive. This status is often linked to a shorter “time to first treatment” [6][8].

2. FISH Results: The Chromosomal Roadmap

A FISH test looks for missing or extra pieces of chromosomes in the CLL cells [9].

  • del(13q): This is the most common and most favorable finding. When it appears alone, it is associated with the best long-term outcomes [10].
  • del(11q): Often seen in younger patients with larger lymph nodes; it suggests a more active disease course [1].
  • Trisomy 12: An intermediate finding that often requires closer monitoring [1].
  • del(17p): This is a high-risk finding because it involves the loss of the TP53 gene [11][12].

3. TP53: The “Guardian” Gene

The TP53 gene is like a biological “brake” that stops cancer cells from growing. If you have a del(17p) or a TP53 mutation, your “brakes” aren’t working well [13]. This is critical because these markers identify patients who should not receive traditional chemotherapy, as it is often ineffective for them [14][15]. Instead, these patients are usually treated with targeted therapies like BTK inhibitors (e.g., ibrutinib) when it is time to start treatment [16][17].

Risk Interpretation Guide

Genetic Finding Typical Outlook Treatment Strategy
Mutated IGHV More stable/Slow growing Long-term “Watch and Wait” is common [7].
Unmutated IGHV More active May require treatment sooner; responds well to targeted therapy [18].
del(13q) only Most favorable Usually stable for many years [10].
del(17p) or TP53 High risk Avoids standard chemo; uses targeted therapies when treatment is needed [13][14].

Even if you have high-risk markers, your doctor may still recommend “watch and wait” if your blood counts are stable and you feel well. These markers tell us what treatment to use, but your symptoms and blood counts tell us when to start [13][19].

Common questions in this guide

What is the difference between mutated and unmutated IGHV in CLL?
In CLL, having a mutated IGHV status is actually a positive sign, indicating more mature, slower-growing cells. An unmutated IGHV status means the cells are more primitive and the disease may be more active, potentially requiring treatment sooner.
What does a del(17p) or TP53 mutation mean for my CLL treatment?
A del(17p) or TP53 mutation is considered a high-risk marker because it impairs a crucial gene that stops cancer cell growth. Because traditional chemotherapy is often ineffective for these markers, doctors typically recommend targeted therapies like BTK inhibitors when treatment is needed.
Why is 'watch and wait' recommended even if I have high-risk genetic markers?
Genetic markers tell your doctor which treatments will work best, but your physical symptoms and blood counts dictate when treatment should actually begin. If your blood counts remain stable and you feel well, watching and waiting is often still the safest initial approach.
What do the Rai and Binet staging systems measure?
The Rai and Binet systems are traditional frameworks that categorize CLL based on physical exams and basic blood tests. They evaluate factors like high white blood cell counts, enlarged lymph nodes, liver or spleen size, and whether you have anemia or low platelets.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What are my Rai and Binet stages, and how much do they factor into your treatment recommendation compared to my genetic markers?
  2. 2.Did my FISH test show a 13q deletion, a 17p deletion, or any other specific chromosomal abnormalities?
  3. 3.Is my IGHV status 'mutated' or 'unmutated,' and what does that mean for the timing of my first treatment?
  4. 4.Do I have a TP53 mutation even if my 17p results were normal?
  5. 5.If I have high-risk markers like del(17p) or unmutated IGHV, why is 'watch and wait' still the standard starting point?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Molecular map of chronic lymphocytic leukemia and its impact on outcome.

    Knisbacher BA, Lin Z, Hahn CK, et al.

    Nature genetics 2022; (54(11)):1664-1674 doi:10.1038/s41588-022-01140-w.

    PMID: 35927489
  2. 2

    Advances in epigenetic alterations of chronic lymphocytic leukemia: from pathogenesis to treatment.

    Zhang X, Wang H, Zhang Y, Wang X

    Clinical and experimental medicine 2024; (24(1)):54 doi:10.1007/s10238-023-01268-x.

    PMID: 38492089
  3. 3

    Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia.

    Rodrigues CA, Gonçalves MV, Ikoma MR, et al.

    Revista brasileira de hematologia e hemoterapia 2016; (38(4)):346-357 doi:10.1016/j.bjhh.2016.07.004.

    PMID: 27863764
  4. 4

    Chronic lymphocytic leukaemia.

    Scarfò L, Ferreri AJ, Ghia P

    Critical reviews in oncology/hematology 2016; (104()):169-82.

    PMID: 27370174
  5. 5

    Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification.

    Strati P, Shanafelt TD

    Blood 2015; (126(4)):454-62 doi:10.1182/blood-2015-02-585059.

    PMID: 26065657
  6. 6

    Time to Treatment Prediction in Chronic Lymphocytic Leukemia Based on New Transcriptional Patterns.

    Mosquera Orgueira A, Antelo Rodríguez B, Alonso Vence N, et al.

    Frontiers in oncology 2019; (9()):79 doi:10.3389/fonc.2019.00079.

    PMID: 30828568
  7. 7

    Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia.

    Visentin A, Facco M, Frezzato F, et al.

    Clinical lymphoma, myeloma & leukemia 2015; (15(10)):612-20.e1-5.

    PMID: 26233718
  8. 8

    Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia.

    Giacopelli B, Zhao Q, Ruppert AS, et al.

    Blood 2019; (134(8)):688-698 doi:10.1182/blood.2019000490.

    PMID: 31292113
  9. 9

    Role of miR-15a/miR-16-1 and the TP53 axis in regulating telomerase expression in chronic lymphocytic leukemia.

    Rampazzo E, Bojnik E, Trentin L, et al.

    Haematologica 2017; (102(7)):e253-e256 doi:10.3324/haematol.2016.157669.

    PMID: 28385779
  10. 10

    The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience.

    Van Dyke DL, Werner L, Rassenti LZ, et al.

    British journal of haematology 2016; (173(1)):105-13 doi:10.1111/bjh.13933.

    PMID: 26848054
  11. 11

    Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?

    Pospisilova S, Sutton LA, Malcikova J, et al.

    Haematologica 2016; (101(3)):263-5 doi:10.3324/haematol.2015.139246.

    PMID: 26928246
  12. 12

    Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders.

    Yi S, Li Z, Zou D, et al.

    Oncotarget 2018; (9(3)):3353-3364 doi:10.18632/oncotarget.23261.

    PMID: 29423051
  13. 13

    Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial.

    Al-Sawaf O, Fischer K, Herling CD, et al.

    European journal of haematology 2017; (98(3)):254-262 doi:10.1111/ejh.12825.

    PMID: 27862308
  14. 14

    TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics.

    Campo E, Cymbalista F, Ghia P, et al.

    Haematologica 2018; (103(12)):1956-1968 doi:10.3324/haematol.2018.187583.

    PMID: 30442727
  15. 15

    Chronic lymphocytic leukaemia: from genetics to treatment.

    Bosch F, Dalla-Favera R

    Nature reviews. Clinical oncology 2019; (16(11)):684-701 doi:10.1038/s41571-019-0239-8.

    PMID: 31278397
  16. 16

    Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.

    Barr PM, Robak T, Owen C, et al.

    Haematologica 2018; (103(9)):1502-1510 doi:10.3324/haematol.2018.192328.

    PMID: 29880603
  17. 17

    Mice Overexpressing Wild-Type RRAS2 Are a Novel Model for Preclinical Testing of Anti-Chronic Lymphocytic Leukemia Therapies.

    Hortal AM, Villanueva A, Arellano I, et al.

    Cancers 2023; (15(24)) doi:10.3390/cancers15245817.

    PMID: 38136362
  18. 18

    Frontline Therapy of CLL: Evolving Treatment Paradigm.

    Boddy CS, Ma S

    Current hematologic malignancy reports 2018; (13(2)):69-77 doi:10.1007/s11899-018-0438-x.

    PMID: 29480432
  19. 19

    Chronic lymphocytic leukaemia.

    Hallek M, Shanafelt TD, Eichhorst B

    Lancet (London, England) 2018; (391(10129)):1524-1537 doi:10.1016/S0140-6736(18)30422-7.

    PMID: 29477250

This page explains CLL staging and genetic markers for educational purposes. Your hematologist or oncologist is the best source for interpreting your specific pathology report and test results.

Get notified when new evidence is published on B-cell chronic lymphocytic leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.